Market Overview - The Hong Kong stock index showed an upward trend in early trading on January 27, with the Hang Seng Index rising by 1.07% to 27,053.05 points, the Hang Seng Tech Index increasing by 0.2% to 5,737.27 points, and the China Enterprises Index up by 0.86% to 9,225.77 points [1] - Major technology stocks exhibited mixed performance, with Alibaba up by 2.18%, Tencent Holdings up by 1.08%, JD.com down by 1.38%, and Meituan down by 0.51% [1] - Gold stocks continued to rise, with Zijin Mining and Zijin Gold International reaching historical highs, while insurance stocks were active, with AIA Group rising over 3% [1] Company News - China Power (02380.HK) reported a total electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual cumulative total of approximately 126 million MWh, down by 1.27% year-on-year [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Singularity National Peak (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug research and development platform [3] - Vison Pharmaceutical-B (02561.HK) received approval from the National Medical Products Administration for the marketing authorization application of injectable Long-acting Growth Hormone [4] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [5] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization of BRIMOCHOL PF for presbyopia treatment in Singapore and Vietnam through partnerships with AFT and Qianshou [5] - Heng Rui Pharmaceutical (01276.HK) received a clinical trial approval notice for SHR-1049 injection [6] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by relevant bondholder meetings [7] - Aibo Technology Holdings (08279.HK) entered into a technical service agreement with Hong Kong Gold Trading Co., Ltd. [8] - Future Data Group (08229.HK) signed a strategic cooperation framework agreement with Linghe Culture [9] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuan Zhi's initial public offering [10] Institutional Insights - According to招商国际, the Hong Kong stock market is currently in an earnings vacuum period, with high growth expectations for new economy sectors boosting market confidence. The appreciation of the RMB is favorable for Hong Kong stocks, and domestic policies are focusing on technological innovation and expanding domestic demand [11] - Citigroup believes that the outlook for Hong Kong stocks is better than that of A-shares, with optimism for 2026 supported by both southbound and foreign capital. However, potential risks include high overseas interest rates and corporate earnings falling short of expectations [11] - Huatai Securities noted that technology and cyclical "consumables" are expected to lead the recovery of Hong Kong stocks, with external pressures easing and domestic macro data stabilizing [11] - Guoyuan International suggests that the current environment may allow Hong Kong stocks to continue outperforming U.S. stocks, driven by low long-term valuation levels and potential recovery in domestic credit demand [12]

Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [1] Company Performance - Yongtai Bio-B surged over 12% [1] - Kexing Pharmaceutical-B increased nearly 10% [1] - Tiansheng Pharmaceutical-B rose over 5% [1] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [1]

Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [2] Group 1: Stock Performance - Yongtai Bio-B surged over 12% [2] - Keji Pharmaceutical-B increased nearly 10% [2] - Tiansheng Pharmaceutical-B rose over 5% [2] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [2]

Core Insights - The article highlights the emergence of "ten-bagger" stocks in the A-share and Hong Kong markets over the past year, particularly in the pharmaceutical, non-bank financial, and computer sectors [1][2][5] - These ten-bagger stocks typically exhibit characteristics of small market capitalization and high growth in performance [5][6] A-share and Hong Kong Market Overview - From August 2024 to July 2025, A-shares produced 7 ten-bagger stocks, while Hong Kong saw 14 ten-bagger stocks among those with an average daily trading volume exceeding 10 million HKD [2] - The average market capitalization of the identified ten-bagger stocks is approximately 19.47 billion RMB, with a median market capitalization of 10.08 billion RMB [5] Industry Analysis Pharmaceutical Sector - The pharmaceutical industry has seen significant growth, with four ten-bagger stocks: Gilead Sciences, Deciphera Pharmaceuticals, Kintor Pharmaceutical, and Hengrui Medicine, driven by performance reversal expectations, policy benefits, and incremental business opportunities [6][9] - The industry is expected to achieve a net profit of 140.57 billion RMB in 2024, a decrease of 12.97% year-on-year, but an improvement compared to the previous year's decline of 18.90% [6] Non-bank Financial Sector - The non-bank financial sector includes ten-bagger stocks such as Shenwan Hongyuan, Yao Cai Securities, and Guotai Junan International, benefiting from performance recovery and policy support [10] - The securities industry is projected to see a revenue increase of 11.15% year-on-year in 2024, with net profit expected to rise by 21.35% [10] Computer Sector - The computer sector's ten-bagger stocks, including Aijun Software, Lian Di Information, and Kingsoft Cloud, are primarily linked to AI concepts and financial applications [11] - Aijun Software has expanded its offerings in big data and AI, while Lian Di Information has seen significant growth in financial sector orders [11] Notable Individual Stocks - Gilead Sciences has capitalized on the growing global market for GLP-1 weight loss drugs, achieving significant clinical results with its oral GLP-1R agonist [9] - Kintor Pharmaceutical has made breakthroughs in CAR-T therapy for solid tumors, showcasing its potential in the cell therapy field [9] - Hengrui Medicine's advancements in antibody drug development have led to significant collaborations with international pharmaceutical companies [8]

Group 1 - The core viewpoint of the report indicates that after a period of consolidation, the Hong Kong stock market is expected to reach new highs, supported by factors such as a potential resolution in the trade war, improvement in Sino-US relations, and a restart of the US interest rate cut cycle [2][4]. - The Hang Seng Index experienced a "V" shaped trading pattern, closing at 25,524 points, down 37 points or 0.15%, with a notable increase in trading volume, particularly in the Stock Connect segment [2][3]. - The report highlights that the Northbound capital flow remains strong, with a net inflow of HKD 12.7 billion, marking a 37.5% increase from the previous day, and a total net inflow exceeding HKD 45 billion over the last four trading days [3]. Group 2 - The report discusses the upcoming review of the Hang Seng Index, with significant increases in the average market capitalization thresholds for inclusion and exclusion, rising to HKD 7.33 billion and HKD 4.63 billion respectively, reflecting increases of 21.6% and 17.8% [6]. - It is anticipated that 20 non A+H stocks and 5 new A+H stocks will become new additions to the Stock Connect, with 22 non A+H stocks expected to qualify based on average market capitalization and turnover rates [6][8]. - The report identifies specific stocks that are particularly noteworthy for potential inclusion in the Stock Connect, including Nanshan Aluminum International (2610.HK) and KANAT Optics (2276.HK), among others [8].

Market Overview - The Hong Kong stock market showed volatility, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion HKD, with net inflows of 484 million HKD recorded in the Hong Kong Stock Connect [1] - The Hang Seng Index reached a high of 24,994.14 points, marking a 0.68% increase, with significant contributions from the technology sector [1][3] U.S. Market Performance - Investor optimism regarding corporate earnings outweighed concerns about trade developments, leading to gains in the U.S. stock market [2] - The S&P 500 Index closed at 6,305 points, up 0.1%, while the Nasdaq rose by 78 points or 0.4% to 20,974 points [2] - Notable stock movements included Alphabet rising by 2.8% ahead of its earnings report, while Tesla fell by 0.4% [2] Investment Opportunities - The report emphasizes the low valuation of Hong Kong stocks, inflows from mainland investors, and increased trading activity as positive indicators for the market's medium to long-term outlook [3] - Suggested sectors for investment include: 1. Technology sectors such as artificial intelligence, robotics, semiconductors, and industrial software [3] 2. Innovative pharmaceutical sectors supported by policy initiatives, along with traditional Chinese medicine and healthcare [3] 3. Coal, oil, gas, and telecommunications sectors benefiting from low-risk interest rates in mainland China [3] 4. Consumer sectors like clothing, footwear, and dining that are currently undervalued [3] Key Company Insights - The report highlights the performance of major companies, including: - China Railway Group, which is expected to see a decline in revenue and net profit for 2024, but has a strong order backlog providing future earnings support [10] - Alibaba's stock buyback and BYD's production milestone of 13 million electric vehicles are noted as significant developments [11] - The report suggests monitoring companies like China CRRC and Times Electric for their roles in the railway equipment manufacturing sector, which is poised for growth due to substantial infrastructure investments [9]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of July 20, 2025 [1] Core Insights - The establishment of a positive innovation cycle is driving value enhancement in the pharmaceutical sector, particularly through overseas collaborations and the increasing recognition of the value of PD-1/VEGF dual antibodies [2] - The focus on tri-antibodies is rising, with significant potential for competition in first-line treatments, as evidenced by recent collaborations and promising clinical data [3] - The trend towards more effective and scientifically-backed weight loss solutions is evident, with GLP-1 drugs projected to generate over $50 billion in global sales in 2024, significantly boosting capital interest [5] - The trend in autoimmune drug development is shifting towards innovative therapies, with notable advancements in dual-target fusion proteins [6] - The approval of Vuxinib (伏欣奇拜单抗) marks a significant milestone in biological treatments for gout, with a substantial market potential due to the increasing prevalence of hyperuricemia and gout [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.91 percentage points in the past week, with a weekly increase of 4.00%, ranking second among 31 primary industry indices [19] - Over the past month, the pharmaceutical sector outperformed the CSI 300 index by 5.90 percentage points, with an increase of 11.51%, ranking fourth among primary industry indices [21] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector has shown a 14.50% increase over the past six months, outperforming the CSI 300 index by 4.46 percentage points [36] - The current PE (TTM) for the pharmaceutical sector is 37.25, which is above the five-year historical average of 32.24 [39] 3. Recent Research Achievements - The research team has published several in-depth reports highlighting the positive trends in supply and demand within the pharmaceutical industry, including the growth of blood products and the acceleration of the import substitution process in inhalation preparations [44] 4. Recent Industry Policies and News - Recent measures from the National Medical Insurance Administration aim to support the high-quality development of innovative drugs, enhancing their market access and clinical application [46] - Notable industry news includes the approval of new indications for existing drugs and significant collaborations between major pharmaceutical companies [47][49]

Group 1: Hong Kong Stock Market Highlights - Yunfeng Financial (00376) surged over 21% as the company plans to strategically invest in digital currency and AI sectors [1] - China Merchants Securities (06099) opened nearly 15% higher and is currently up over 4% after receiving approval for a virtual asset license [1] - GDS Holdings (09698) rose over 7% as its Southern GDS data center REIT concluded public investor fundraising ahead of schedule [1] - Hillstone Technology (01478) increased nearly 6% with positive earnings expectations, and Citigroup anticipates a favorable market reaction [1] - Sunny Optical Technology (02382) briefly rose over 3% and is currently up over 1% as its lithography equipment successfully entered Shanghai, indicating a shift to mass production [1] - Kintor Pharmaceutical (02171) saw an early gain of over 3% after achieving positive results in the European patent opposition process [1] - Bilibili (09626) rose over 5% as HSBC expressed optimism about its gaming and advertising business, with new games planned for 2025 [1] - Solar stocks experienced a decline, with institutions citing electricity prices affecting the stable profitability of new energy projects [1] Group 2: U.S. Stock Market Highlights - The U.S. nuclear sector saw gains, with NuScale Power (SMR.US) up 12.38% and Oklo Inc (OKLO.US) up 11.29%, following comments from the U.S. Energy Secretary about a nuclear revival [3] - Autodesk (ADSK.US) rebounded 5.05% after a period of decline, expressing confidence in its cloud and AI business strategies [3] - Sonnet BioTherapeutics (SONN.US) surged 86.46% due to a merger announcement, forming a cryptocurrency financial company valued at $888 million [3] - Quantum stocks rose, with D-Wave Quantum (QBTS.US) up 6.89% and Quantum Computing (QUBT.US) up 8.66% [3] - Hims & Hers Health (HIMS.US) increased 8.64% as it plans to enter the Canadian market with a generic drug following the expiration of a patent [4] - Rocket Lab (RKLB.US) rose 10.71% after Citigroup raised its target price, noting a significant increase in global space technology investments [4] - Nvidia-related stocks mostly strengthened as Jensen Huang made his third visit to China this year [5] - Cryptocurrency stocks collectively rose, with Bitcoin surpassing $120,000, driven by upcoming legislative reviews in the U.S. [5] - Tesla (TSLA.US) gained 1.08% amid investor speculation regarding a stake in xAI [5] - Netflix (NFLX.US) rose 1.35% ahead of its upcoming earnings report, with analysts projecting significant revenue growth [6]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [7]. Core Insights - The National Healthcare Security Administration has initiated the adjustment work for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which is expected to include multiple new drugs for negotiation [2]. - From July 1, 2024, to June 30, 2025, approximately 19 oncology drugs and 23 non-oncology drugs are anticipated to be approved and may participate in the 2025 medical insurance negotiations [2]. Summary by Sections 1. Weekly New Drug Market Review - From June 30, 2025, to July 4, 2025, the top five companies in the new drug sector by stock price increase were: - Zai Lab (45.00%) - Sanofi (36.30%) - Frontier Biopharma (30.60%) - Micron Biomedicine (30.50%) - Kangfang Biopharma (25.50%) - The top five companies with the largest declines were: - Oconview (-12.90%) - Kexin Pharmaceuticals (-9.10%) - Dongyao Pharmaceuticals (-6.70%) - Lepu Biopharma (-6.40%) - Yifang Biopharma (-3.60%) [1][16]. 2. Weekly New Drug Industry Analysis - The adjustment work for the 2025 medical insurance catalog has begun, allowing new generic drugs approved between January 1, 2020, and June 30, 2025, to apply for inclusion [2]. - The expected new drugs for negotiation in 2025 will primarily be those approved between July 1, 2024, and June 30, 2025 [2]. 3. Weekly New Drug Approval & Acceptance Status - This week, 22 new drugs or new indications received approval for market entry, while one new drug application was accepted [3][26]. 4. Weekly New Drug Clinical Application Approval & Acceptance Status - A total of 46 new drug clinical applications were approved this week, and 31 new drug clinical applications were accepted [4][32]. 5. Key Domestic Market Events - Key events included the approval of a MET inhibitor by Hutchison China MediTech for treating advanced non-squamous non-small cell lung cancer and the approval of an anti-IL-1β monoclonal antibody by Junshi Biosciences for treating acute attacks of gouty arthritis [5][12]. 6. Key Overseas Market Events - Notable overseas events included Moderna's positive progress in its seasonal flu mRNA vaccine study, Regeneron's accelerated approval of a dual antibody for multiple myeloma, and Pfizer's announcement of a significant reduction in bleeding rates in hemophilia patients [13].

Group 1: Industrial Enterprises Profit Analysis - In the first five months of 2025, profits of industrial enterprises above designated size decreased by 1.1% year-on-year, with a significant drop of 9.1% in May [3][4] - The decline in profits is attributed to multiple factors including reduced working days, tariff adjustments causing delays in orders and production, and a decrease in both volume and price, leading to a 2.7% increase in operating income [4][5] - The profit margin for the first five months was 4.97%, down 4.2% year-on-year, indicating a worsening profitability situation for industrial enterprises [4][5] Group 2: Macroeconomic Outlook - The macroeconomic report indicates that the Chinese economy has maintained stable growth despite external pressures, with a GDP growth of 5.4% in Q1 2025, surpassing market expectations [8] - The report anticipates a gradual slowdown in economic growth in the latter half of 2025 due to declining export momentum and diminishing policy effects, with infrastructure investment being crucial for achieving annual GDP growth targets [8][9] - The fiscal policy is expected to remain proactive, with potential measures including the issuance of government bonds to support economic growth [9] Group 3: Fixed Income Market Strategy - The fixed income market saw a significant increase in the issuance of government bonds in the first half of 2025, with net financing close to 3.4 trillion yuan, double that of the same period in 2024 [10][11] - The report suggests that the bond market will remain in a volatile state, with limited opportunities for significant trends, emphasizing the importance of tactical trading strategies [16] - The anticipated monetary policy adjustments, including potential rate cuts, are expected to influence the bond market dynamics positively [16] Group 4: Metal Industry Investment Strategy - The metal industry report highlights strong price trends for copper, aluminum, gold, cobalt, and rare earth elements, with gold expected to maintain upward momentum due to ongoing geopolitical tensions and anticipated interest rate cuts [23][25] - The report notes a recovery in rare earth export demand, driven by the growth in the new energy and robotics sectors, following recent adjustments in export controls [25][26] - Investment strategies recommend focusing on companies with strong resource bases and cost control capabilities in the gold and rare earth sectors [27] Group 5: Pharmaceutical and Biotechnology Sector - The pharmaceutical sector is experiencing positive momentum, with significant developments in high-end medical device innovation and new drug approvals [28][29] - The report indicates a rebound in the pharmaceutical market, driven by improved policies and a reduction in negative impacts from previous regulations [30] - Investment opportunities are suggested in sectors benefiting from policy optimization and improving performance metrics, particularly in the CXO and medical device segments [30]